ORCA Therapeutics B.V. is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents (ORCA).

These agents are derived from naturally occurring viruses and are engineered to selectively destroy cancer cells,
while healthy cells are left unharmed. In addition, oncolytic viruses are used as efficient delivery agents to express anti-cancer products at high levels in cancer cells and as anti-cancer vaccines that present cancer antigens to the immune system.

 
 

News

8 November 2011
ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government
read more +
 

31 October - 2 November 2011
Orca Therapeutics presenting at the Bio-Europe meeting in Düsseldorf
read more +
 

4 July 2011
ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology
read more +

 

Job Opportunities

There is currently no opening
   

Terms of use | Disclaimer | Contact

© 2009 ORCA Therapeutics B.V. | Photography: Wen L. Dong, PhD